A public health crisis of this magnitude demands an integrated approach. Prevention is only one element of a strategic response, but one that must be sustained and expanded, even as gravely affected communities deal with competing priorities. This session presents the results of research and cost-benefit analyses of substance abuse prevention programs, policies, and practices conducted for the Center for Substance Abuse Prevention in order to update the 2008 publication by the Substance Abuse and Mental Health Services Administration, "Prevention Dollars and Sense: A Cost-Benefit Analysis." It focuses on a review of more than 300 universal, selective, and indicated approaches specific to prevention of misuse and abuse of pharmaceutical and illicit opioid drugs and reduction of associated risks and harms. Findings include results of analysis of outcomes and effects of school and community-based prevention programs for youth, which identify all significant effects relative to reducing initiation of drug use among middle and high school students; a review of prescription drug monitoring program utilization mandates in all 50 states; research on cost-benefits and impact on opioid overdose fatality rates; and cost savings of preventing opioid overdose fatalities through expanded access to naloxone. Presenters will cover trends in initiation of nonmedical use of prescription drugs among youth, overdose deaths and suicides among high-risk groups, prevention of opioid analgesic misuse use among older adults, outcomes for programs that target high-risk pregnant women, and a national landscape review of promising programs.
This session is accredited for the following accreditation types: CME, CNE, CPE, APA, AAFP, AAHCPAD*, NAADAC*, ASWB*
*State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit.